Fixing Trials Requires A True Commitment To Patient-Centricity

By Ed Miseta, Chief Editor, Clinical Leader

Everyone wants to improve clinical trial time, cost, and efficiency. The time and cost of performing trials continues to rise, as does the number of compounds that fail to make it through to consumers. Less than 12 percent of the drugs entering clinical testing will ultimately receive FDA approval. Even representatives of the FDA now admit our process for performing trials is “broken.”